Evidence map›Paper›PMID 37895969›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend

Samuel Kakraba, Srinivas Ayyadevara, Nirjal Mainali, Meenakshisundaram Balasubramaniam, Suresh Bowroju, Narsimha Reddy Penthala, Ramani Atluri, Steven W Barger, Sue T Griffin, Peter A Crooks and 1 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Samuel KakrabaDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.ORCID 0000-0002-6362-5126
Srinivas AyyadevaraDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Nirjal MainaliDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.ORCID 0000-0001-9679-1174
Meenakshisundaram BalasubramaniamDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Suresh BowrojuDepartment of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.ORCID 0000-0001-9906-0625
Narsimha Reddy PenthalaDepartment of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Ramani AtluriDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Steven W BargerDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Sue T GriffinDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Peter A CrooksDepartment of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Robert J Shmookler ReisDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.ORCID 0000-0002-4691-0734
University of Arkansas for Medical Sciences · USCentral Arkansas Veterans Healthcare System · US

Funding

THE APOE-APP AXIS IN ALZHEIMER PATHOGENESISP01AG012411 · NIA · UNIV OF ARKANSAS FOR MED SCIS · PI SHMOOKLER REIS, ROBERT JOSEPH · 1995 to 2020
$25.0M
Role of glucose transport in Alzheimer's disease pathogenesisR01AG084473 · NIA · UNIV OF ARKANSAS FOR MED SCIS · PI Steven W Barger · 2023 to 2026
$1.5M
BLRD VA I01 BX001655BLRD VA IK6 BX004851NIA NIH HHS P01 AG012411NIA NIH HHS R01 AG084473
6 · The paper itself

Abstract

Chronic, low-grade inflammation has been implicated in aging and age-dependent conditions, including Alzheimer's disease, cardiomyopathy, and cancer. One of the age-associated processes underlying chronic inflammation is protein aggregation, which is implicated in neuroinflammation and a broad spectrum of neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's diseases. We screened a panel of bioactive thiadiazolidinones (TDZDs) from our in-house library for rescue of protein aggregation in human-cell and

Indexed as

aggregationAlzheimer’s diseaseglycogen synthase kinase 3β (GSK3β)molecular modelingneurodegenerationneurodegenerative diseaseprotein aggregationproteostasisthiadiazolidinones (TDZDs)

Identifiers

PMID37895969
PMCPMC10610358
OpenAlexW4387843635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.